Abstract Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) has shown beneficial effects against heart failure. Because cardiovascular diseases (mainly diabetic cardiomyopathy) are the leading cause of death in diabetic patients, the use of EMPA could be, simultaneously, cardioprotective and antidiabetic, reducing the risk of death from cardiovascular causes and decreasing the risk of hospitalization for heart failure in T2DM patients. Interestingly, recent studies have shown that EMPA has positive benefits for people with and without diabetes. This finding broadens the scope of EMPA function beyond glucose regulation alone...
International audienceAbstract Diabetes mellitus (DM)-induced cardiac morbidities have been the lead...
Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced the risk...
Aims Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse p...
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment...
Mass spectrometry raw data for the manuscript Multi-omics analysis reveals attenuation of cellular s...
Abstract Empagliflozin, a sodium-glucose co-transporter (SGLT) inhibitor, reduces heart failure and ...
To explore mechanisms by which SGLT2 inhibitors protect diabetic hearts from heart failure, we exami...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
International audienceAbstract Background Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Empagliflozin (EMPA), an SGLT2 inhibitor (with a low affinity for SGLT1) has attracted much attentio...
Aims/hypothesis: Changes in cardiac metabolism and ion homeostasis precede and drive cardiac remodel...
International audienceAbstract Diabetes mellitus (DM)-induced cardiac morbidities have been the lead...
Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced the risk...
Aims Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse p...
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment...
Mass spectrometry raw data for the manuscript Multi-omics analysis reveals attenuation of cellular s...
Abstract Empagliflozin, a sodium-glucose co-transporter (SGLT) inhibitor, reduces heart failure and ...
To explore mechanisms by which SGLT2 inhibitors protect diabetic hearts from heart failure, we exami...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
International audienceAbstract Background Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Empagliflozin (EMPA), an SGLT2 inhibitor (with a low affinity for SGLT1) has attracted much attentio...
Aims/hypothesis: Changes in cardiac metabolism and ion homeostasis precede and drive cardiac remodel...
International audienceAbstract Diabetes mellitus (DM)-induced cardiac morbidities have been the lead...
Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced the risk...
Aims Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse p...